See clearly and quickly
with Qynapse’s AI-powered
neuroimaging software platform.
Our quest is to enhance your clinical trial design and increase the likelihood of trial success by leveraging our precise and objective AI-powered neuroimaging software platform.
Increase your clinical trial success.
For clinical researchers, pharma and biotech, our neuroimaging software platform QyScore® and our predictive research-use-only platform QyPredict®, has the potential to dramatically increase the likelihood of a successful clinical trial by enhancing trial design, providing measurement precision, simplifying and decentralizing the clinical trial process to improve patient selection and endpoint protection.
- Improve pre-identification of patients by analyzing thousands of imaging datasets simultaneously and in conjunction with other clinical markers
- Automate image pre-processing, quality control and image analysis with results you can trust
- Provide more objectivity and automation to create the potential for more precise measurement of drug efficacy and safety for clinical trials
The future of neuroimaging is here.
Qynapse combines global scientific expertise and proprietary AI with a normative dataset to provide precise and reliable imaging measures, such as:
- Whole brain, white matter and grey matter by lobe
- White matter abnormalities and brain substructures
- Diffusion and functional MRI
- Basal ganglia and thalamus
- Cerebellum, ventricles, brain stem and spinal cord volumes
- Amyloid PET and functional MRI
That’s why Qynapse has global support from the most renowned and respected CNS disease experts and principal investigators.
Qynapse’s research and clinical trials platform:
Decreases image reading variability and segmentation by 89%
Largest Normative Dataset
of over 10,000 brain scan images of healthy and disease-specific controls
Over 200 automated measures of neuroinflammation and neurodegeneration
Bruno Dubois, MD, PhD
Professor of Neurology | Sorbonne University, Director of the Institute of Memory and Alzheimer’s Disease (IM2A) | Pitié Salpêtrière Hospital in Paris
In light of the recent breakthrough for Alzheimer’s patients – the approval of new treatment options by the FDA, Qynapse’s vision is becoming even more critical to advance the early detection of Alzheimer’s disease and to precisely monitor the therapy efficacy and safety.
Founder & CEO | Qynapse
When someone you love is declining mentally, there’s nothing worse than not having a clear diagnosis as to why. That’s why Qynapse is on a mission to transform time to diagnosis and the accuracy for diagnosis for CNS disease.
Srinivas Peddi, MD
Radiologist & Board Member | Tower Imaging Medical Group
When you remove air from a ball, it’s hard to figure that out until it’s lost a lot of volume. But if we had a tool that would let us measure more precisely? That’s super helpful. And that’s what Qynapse provides.
Former CEO | UnitedHealthcare Specialty Benefits
Payers have developed very sophisticated systems and data sets to help their members, healthcare providers and teams make better decisions about healthcare. What Qynapse provides further enhances that decision making, resulting from the whole being greater than the sum of the parts.
David Merrill, MD, PhD
Director | Pacific Brain Health Center Pacific Neuroscience Institute
I’m excited to use QyScore® to quantify both volumetric and white matter integrity in our patients – bringing such an important layer of precision and objectivity to inform our clinical decisions.
Marwan N. Sabbagh
MD, FAAN, CCRI
Going from a diagnostic accuracy of 66-70% to better than 90% is today the most pressing topic for the Alzheimer’s disease community. I am glad to see innovative organizations like Qynapse leading the way and contributing to transform the diagnosis of Alzheimer’s disease.
If you’re a clinical researcher, pharma or biotech, our team is standing by, ready to demonstrate the power of Qynapse. Reach out and we’ll be in touch soon.
Qyscore® is a medical device software FDA-cleared – class II and CE-marked – class IIa.
Indications for Use in the U.S. (FDA): QyScore® is intended for automatic labeling, visualization and volumetric quantification of segmentable brain structures and lesions from a set of MR images. Volumetric data may be compared to reference percentile data. QyScore® is not intended for use in clinical scenarios that require evaluation of the number of the white matter hyperintensities.
Indications for Use in Europe (CE): QyScore® is an advanced processing and visualization software for automatic labeling and volumetric quantification of segmented central nervous system structures for patients older than 18 years of age. The software is intended to be used by medical personnel or neuroimaging trained personnel to support diagnosis of central nervous system diseases.